American Journal of Respiratory and Critical Care Medicine

One of every 650 African Americans (0.15%) is born with sickle cell disease and about 8% are heterozygous for the sickle cell gene. According to the United States Census Bureau there were 35,509,000 African Americans counted in the year 2000, which would indicate that there are approximately 50,000 patients with sickle cell anemia in this country. Thirty five per cent of the African American population was between 30 and 54 yr of age in the year 2000. This demographic explains the increasing number of adult patients with sickle cell disease. However, the increased number of adults with sickle cell anemia is due only in part to population growth. Mortality rates for children with sickle cell anemia have declined because of penicillin prophylaxis, Haemophilus influenzae and Streptococcus pneumoniae vaccination, widespread implementation of newborn screening programs for early detection, and improvements in parental education (1-5). Despite significant improvements in the life expectancy of patients with sickle cell disease the median age at death is 42 yr for men and 48 yr for women (2). Pulmonary complications account for a large proportion of deaths among adults with sickle cell anemia (Table 1) (2, 6-8). According to the Cooperative Study of Sickle Cell Disease (CSSCD), a prospective multicenter study of 3,764 patients, more than 20% of adults likely had fatal pulmonary complications of sickle cell anemia (2). Acute and chronic pulmonary complications of sickle cell anemia are common but often underappreciated by healthcare providers. These conditions have clearly emerged as major threats to the well-being and longevity of patients with sickle cell disease.

Table 1.  MORTALITY ATTRIBUTABLE TO PULMONARY DISEASE IN PATIENTS WITH SICKLE CELL ANEMIA

StudyYearDeaths Due to Pulmonary Causes
Platt and coworkers (2)199436 of 172 (21%)*
Gray and coworkers (6)199111 of 18 (61%)
Powars and coworkers (7)198811 of 13 (85%)
Thomas and coworkers (8)198260 of 241 (25%)§

* Specific pulmonary events at the time of death include acute chest syndrome (29 of 36); tuberculosis (3 of 36), sudden death (3 of 36), and pulmonary hypertension (1 of 36).

Specific pulmonary events at the time of death include acute chest syndrome (9 of 11), pulmonary artery thrombosis (1 of 11), and asthma (1 of 11).

Specific pulmonary events at the time of death include acute chest syndrome (11 of 11).

§ Specific pulmonary events at the time of death include acute chest syndrome (47 of 60) and pulmonary thromboembolism (13 of 60).

Patients with sickle cell anemia frequently develop acute pulmonary complications of their illness including asthma, thromboembolism, and acute chest syndrome. A number of studies suggest that asthma is a significant comorbidity in patients with sickle cell anemia. Santoli and coworkers measured pulmonary function in 49 patients with sickle cell anemia and found that 37% of the patients had obstructive lung disease, defined by a ratio of the forced expiratory volume in 1 s to the forced vital capacity (FEV1/FVC) <80% of predicted with normal total lung capacity. Twenty per cent of these patients had mixed obstructive and restrictive pulmonary function, and 20% had restrictive defects alone (9). In a retrospective analysis of 63 children with sickle cell disease receiving routine pulmonary function testing, 35% had obstructive lung disease (10). In one of the few controlled studies, Leong and Stark evaluated 40 patients with sickle cell disease and 10 sibling control subjects. They found that approximately 60% of the patients with sickle cell disease had airway reactivity (to cold air challenge) whereas none of the control subjects had reactive airways (11). The effects of uncontrolled asthma and the impact of intensive therapy on other complications of sickle cell anemia, such as vaso-occlusive crisis and the acute chest syndrome, have not been explored.

People with sickle cell disease appear, on the basis of natural history and evidence from autopsy, to be at increased risk for thromboembolism (8, 12, 13). This observation has been attributed to a putative hypercoagulable state. Although controversial, several mechanisms have been proposed to explain this hypercoagulability including platelet reactivity, hydroxyl radical formation, fibronectin and thrombospondin elevation, deficient proteins S and C, and elevated levels of Factor VIII and tissue factor (14-18). There are no comprehensive epidemiological studies assessing the incidence and prevalence of thromboembolism in patients with sickle cell anemia.

Acute chest syndrome is the most common cause of death and the second most common cause of hospitalization of adults with sickle cell anemia (2, 8, 13). The acute chest syndrome is defined as a new pulmonary infiltrate on chest radiograph accompanied by fever, chest pain, and a variety of respiratory symptoms including coughing, wheezing, and tachypnea (19, 20). Both the CSSCD and the Multi-Center Acute Chest Syndrome Study (MACSS), a prospective study of 671 episodes of acute chest syndrome in 538 patients, found that acute chest syndrome often develops after vaso-occlusive crisis (2, 19). Multiple factors may contribute to the respiratory distress associated with the acute chest syndrome, including infection (21, 22), pulmonary fat embolism (23, 24), iatrogenic fluid overload, hypoxemia and atelectasis secondary to splinting from painful rib and sternal infarctions (25-27), and pulmonary vascular obstruction due to sickling and endothelial adherence of erythrocytes resulting in infarction of the pulmonary parenchyma (19). The pathogenesis of acute chest syndrome has been reviewed (20, 28, 29).

Most patients with sickle cell anemia develop abnormal pulmonary function characterized by airway obstruction, restrictive lung disease, abnormal diffusing capacity, and hypoxemia (7, 9, 10, 30-32). In a series of 16 young adults (20–40 yr of age, with sickle cell anemia and no history of pulmonary disease) who participated in physiologic studies at the National Institutes of Health, mean arterial Pao2 was 89 ± 8.7 mm Hg (33). Chronic occult pulmonary injury by similar mechanisms invoked for the acute chest syndrome may be the cause of these pulmonary function abnormalities.

Pulmonary hypertension is increasingly recognized as a complication of sickle cell anemia (34-41). Retrospective studies of echocardiograms performed at tertiary care sickle cell disease centers have reported that up to 40% of patients have moderate to severe pulmonary hypertension (40, 41). Sutton and colleagues (40) reviewed echocardiograms of 60 consecutive patients with sickle cell anemia. Twelve of these patients had tricuspid regurgitant jet velocities of greater than 2.5 m/s with calculated mean pulmonary systolic pressure of 53 mm Hg and evidence of right ventricular pressure overload (dilation of the right ventricle with paradoxical motion of the septum). Hemodynamic studies of 10 sickle cell patients with cardiopulmonary symptomatology demonstrated elevated pulmonary systolic and diastolic pressures (median, 50/25 mm Hg; range, 25/12–89/35 mm Hg), high cardiac outputs (median, 9.2 L/min; range, 3.1–14.5 L/min) and normal to high pulmonary capillary wedge pressures (median, 17 mm Hg; range, 12–24 mm Hg) (38). Similar measurements in sickle cell patients have been published by other investigators (34, 35, 42, 43). The hemodynamic profiles differ from patients with primary pulmonary hypertension in that the pulmonary pressures tend to be lower and the cardiac outputs are higher, resulting in more modest elevation in pulmonary vascular resistance. The mean values of pulmonary vascular resistance from three studies ranged from 250 to 329 dyn/s per cm5 (35, 38, 43).

To reduce the inherent bias in retrospective analyses of echocardiograms performed for other clinical indications at tertiary care referral centers, we have initiated a prospective screening study of individuals with sickle cell anemia in the greater Washington DC region. Volunteers are being recruited from sickle cell support groups, by multimedia advertisement, and from area sickle cell clinics. Preliminary data from 70 patients participating in this study confirm a prevalence of mild-to-severe pulmonary hypertension of approximately 30% (defined by a tricuspid jet velocity >2.5 m/s).

Sickle cell patients with pulmonary hypertension have a significantly increased mortality rate compared with sickle cell patients without pulmonary hypertension. Sutton and colleagues reported a 40% mortality rate in sickle cell patients with pulmonary hypertension at 22 mo (odds ratio [OR] 7.86, 95% confidence interval [CI] = 2.63 to 23.4), compared with sickle cell patients without pulmonary hypertension (40). Powars and colleagues (7) reported a mean survival of 2.5 yr for sickle cell patients with chronic lung disease and elevated pulmonary artery pressures. Aboubakr and colleagues performed a retrospective analysis of echocardiograms obtained for clinical indications in patients with sickle cell disease. This analysis revealed a 30% prevalence of pulmonary hypertension and a 30% 2-mo mortality rate (44). Investigators at Howard University are monitoring patients with both pulmonary hypertension and sickle cell disease and approximately 50% of these patients have died over a 24-mo period (O. Castro, personal communication). These data suggest that this complication of sickle cell disease, like primary pulmonary hypertension and pulmonary hypertension secondary to other causes, carries a high morbidity and mortality rate. Case series describing the pathologic changes observed in the pulmonary vasculature are summarized in Table 2 (35, 37, 42, 45, 46).

Table 2.  PATHOLOGICAL FEATURES OF SECONDARY PULMONARY HYPERTENSION IN SICKLE CELL DISEASE

ReferenceYearDescription of Pathology
Oppenheimer and coworkers (45)1971Pulmonary artery intimal proliferation and organized, recanalized  thromboemboli
Collins and coworkers (35)1982Recanalized pulmonary arteries; asymmetric intimal hyperplasia of small  and medium-sized pulmonary arteries; right atrial dilation; right  ventricular thickening; patchy pulmonary fibrosis; atrophic fibrosed spleen
Haupt and coworkers (46),  Verresen and coworkers (37)1982 1990Asymmetric intimal expansion; widespread occlusions of small and  medium-sized arteries; old, recanalized thrombi
Case records of the  Massachusetts General  Hospital (42)1983Ectatic and atherosclerotic main and lobar pulmonary arteries; small  recent 1- to 3-mm thromboemboli; old recanalized organized arterial clots;  subtotal occlusion of small pulmonary arteries with medial and intimal  thickening and fibrosis; plexiform lesions; right ventricular hypertrophy;  absent spleen; patchy pulmonary interstitial fibrosis

The etiology of the secondary pulmonary hypertension in individuals with sickle cell disease is likely multifactorial, caused by chronic hypoxemia, in situ thrombosis, and parenchymal and vascular injury due to sequestration of sickle erythrocytes, fat embolization, and infection. Notably, thalassemia is another chronic hemolytic disease that is associated with secondary pulmonary hypertension (prevalence ranging from 10 to 93% depending on the patient population studied) (47-51). There are a number of pathogenic mechanisms that are similar between thalassemia and sickle cell anemia. Both patient populations suffer from chronic hemolysis resulting in the liberation of free hemoglobin, heme, and iron. Plasma and membrane-associated hemoglobin, heme, and free iron can both scavenge nitric oxide and catalyze the formation of reactive oxygen and nitrogen species (52-55). Both patients with sickle cell disease and thalassemia commonly receive blood transfusions, further releasing cell-free hemoglobin into the circulation. Patients with sickle cell anemia are functionally asplenic because of autoinfarction of the spleen in early childhood whereas patients with thalassemia often have their spleens surgically removed. Thus both populations are exposed to a variety of circulating mediators that would otherwise be removed by a functional spleen. In particular, increased platelet levels and platelet-derived mediators such as thrombospondin may contribute to vasculopathy in asplenic patients (56). Activated platelets release thrombospondin, which binds to CD36 surface molecules on endothelial cells and erythrocytes and to sulfated glycans on reticulocytes, resulting in adhesion of red cells to endothelium (57-59). Retarding erythrocyte transit across the capillary bed promotes erythrocyte deoxygenation, intracellular sickle hemoglobin (HbS) polymerization, and vaso-occlusion. Chronic anemia and transfusion in both illnesses result in high cardiac output states and chronic iron deposition leading to injury of organs such as the heart, liver, and possibly the pulmonary vasculature. The higher prevalence of pulmonary vasculopathy observed with these disorders suggests that there may be a distinct syndrome of hemolysis-associated secondary pulmonary hypertension.

The African American population is growing and more children with sickle cell anemia are surviving into adulthood and developing pulmonary complications of their disease. In addition to asthma, thromboembolism, acute chest syndrome, and chronic pulmonary fibrosis, pulmonary hypertension is a common complication of adult patients with sickle cell anemia. Appropriate therapies and strategies for prevention of pulmonary hypertension in sickle cell anemia are unknown. Further research exploring therapies such as oxygen, nitric oxide, prostacyclin, l-arginine supplementation, chronic transfusion, and hydroxyurea is indicated. Other needs for clinical research include the etiology of sudden death, right and left ventricular dysfunction, and the impact of intensive asthma therapy on child and adult clinical outcomes. Clinicians should screen patients with sickle cell anemia for pulmonary hypertension and attempt to identify reversible causes such as hypoxemia, thromboembolism, and asthma. Hydroxyurea, approved by the Food and Drug Administration as a therapy for sickle cell anemia, increases fetal hemoglobin levels, thereby altering the kinetics and equilibrium dynamics of hemoglobin S polymerization, and reduces the rates of vaso-occlusive crisis, acute chest syndrome (ACS), and transfusion (60, 61). Although hydroxyurea has not been studied in sickle cell patients with pulmonary hypertension, we believe that all such patients should be treated with this medication, with the goal of increasing the fetal hemoglobin levels to 20–30% of total hemoglobin (62). For years hematologists and pediatricians have pioneered the research and treatment of patients with sickle cell anemia. The frequency and severity of pulmonary complications in adults with sickle cell anemia now require the attention of pulmonary specialists.

1. Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R, Lobel JS, et al.. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med314198615931599
2. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PPMortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med330199416391644
3. Centers for Disease Control. Mortality among children with sickle cell disease identified by newborn screening during 1990–1994—California, Illinois, and New York. Morb Mortal Wkly Rep 1998;47:169–172.
4. Olney RSPreventing morbidity and mortality from sickle cell disease. A public health perspective. Am J Prev Med161999116121
5. Ashley-Koch A, Yang Q, Olney RSSickle hemoglobin (HbS) allele and sickle cell disease: a HuGE review. Am J Epidemiol1512000839845
6. Gray A, Anionwu EN, Davies SC, Brozovic MPatterns of mortality in sickle cell disease in the United Kingdom. J Clin Pathol441991459463
7. Powars D, Weidman JA, Odom-Maryon T, Niland JC, Johnson CSickle cell chronic lung disease: prior morbidity and the risk of pulmonary failure. Medicine (Baltimore)6719886676
8. Thomas AN, Pattison C, Serjeant GRCauses of death in sickle-cell disease in Jamaica. Br Med J (Clin Res Ed)2851982633635
9. Santoli F, Zerah F, Vasile N, Bachir D, Galacteros F, Atlan GPulmonary function in sickle cell disease with or without acute chest syndrome. Eur Respir J12199811241129
10. Koumbourlis AC, Zar HJ, Hurlet-Jensen A, Goldberg MRPrevalence and reversibility of lower airway obstruction in children with sickle cell disease. J Pediatr1382001188192
11. Leong CS, Stark PThoracic manifestations of sickle cell disease. J Thorac Imaging131998128134
12. Lisbona R, Derbekyan V, Novales-Diaz JAScintigraphic evidence of pulmonary vascular occlusion in sickle cell disease. J Nucl Med38199711511153
13. Vichinsky EP, Styles LA, Colangelo LH, Wright EC, Castro O, Nickerson BAcute chest syndrome in sickle cell disease: clinical presentation and course. Cooperative Study of Sickle Cell Disease. Blood89199717871792
14. Berney SI, Ridler CD, Stephens AD, Thomas AE, Kovacs IBEnhanced platelet reactivity and hypercoagulability in the steady state of sickle cell anaemia. Am J Hematol401992290294
15. Rickles FR, O'Leary DSRole of coagulation system in pathophysiology of sickle cell disease. Arch Intern Med1331974635641
16. Abildgaard CF, Simone JV, Schulman IFactor-8 (antihaemophilic factor) activity in sickle-cell anaemia. Br J Haematol1319671927
17. Solovey A, Gui L, Key NS, Hebbel RPTissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest101199818991904
18. Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RRWhole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood91199842164223
19. Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, et al.Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. N Engl J Med342200018551865
20. Stuart MJ, Setty BNAcute chest syndrome of sickle cell disease: new light on an old problem. Curr Opin Hematol82001111122
21. Kirkpatrick MB, Haynes J, Bass JBResults of bronchoscopically obtained lower airway cultures from adult sickle cell disease patients with the acute chest syndrome. Am J Med901991206210
22. Miller ST, Hammerschlag MR, Chirgwin K, Rao SP, Roblin P, Gelling M, Stilerman T, Schachter J, Cassell GRole of Chlamydia pneumoniae in acute chest syndrome of sickle cell disease. J Pediatr11819913033
23. Vichinsky E, Williams R, Das M, Earles AN, Lewis N, Adler A, McQuitty JPulmonary fat embolism: a distinct cause of severe acute chest syndrome in sickle cell anemia. Blood83199431073112
24. Godeau B, Schaeffer A, Bachir D, Fleury-Feith J, Galacteros F, Verra F, Escudier E, Vaillant JN, Brun-Buisson C, Rahmouni A, et al.Bronchoalveolar lavage in adult sickle cell patients with acute chest syndrome: value for diagnostic assessment of fat embolism. Am J Respir Crit Care Med153199616911696
25. Rucknagel DL, Kalinyak KA, Gelfand MJRib infarcts and acute chest syndrome in sickle cell diseases. Lancet3371991831833
26. Ballas SK, Park CHSevere hypoxemia secondary to acute sternal infarction in sickle cell anemia. J Nucl Med32199116171618
27. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DLIncentive spirometry to prevent acute pulmonary complications in sickle cell diseases. N Engl J Med3331995699703
28. Gladwin MT, Schechter AN, Shelhamer JH, Ognibene FPThe acute chest syndrome in sickle cell disease. Possible role of nitric oxide in its pathophysiology and treatment. Am J Respir Crit Care Med159199913681376
29. Gladwin MT, Rodgers GPPathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. Lancet355200014761478
30. Lonsdorfer J, Bogui P, Otayeck A, Bursaux E, Poyart C, Cabannes RCardiorespiratory adjustments in chronic sickle cell anemia. Bull Eur Physiopathol Respir191983339344
31. Young RC, Rachal RE, Reindorf CA, Armstrong EM, Polk OD, Hackney RL, Scott RBLung function in sickle cell hemoglobinopathy patients compared with healthy subjects. J Natl Med Assoc801988509514
32. Koumbourlis AC, Hurlet-Jensen A, Bye MRLung function in infants with sickle cell disease. Pediatr Pulmonol241997277281
33. Gladwin MT, Schechter AN, Shelhamer JH, Pannell LK, Conway DA, Hrinczenko BW, Nichols JS, Pease-Fye ME, Noguchi CT, Rodgers GP, et al.Inhaled nitric oxide augments nitric oxide transport on sickle cell hemoglobin without affecting oxygen affinity. J Clin Invest1041999937945
34. Durant JR, Cortes FMOcclusive pulmonary vascular disease associated with hemoglobin SC disease. A case report. Am Heart J711966100106
35. Collins FS, Orringer EPPulmonary hypertension and cor pulmonale in the sickle hemoglobinopathies. Am J Med731982814821
36. Simmons BE, Santhanam V, Castaner A, Rao KR, Sachdev N, Cooper RSickle cell heart disease. Two-dimensional echo and Doppler ultrasonographic findings in the hearts of adult patients with sickle cell anemia. Arch Intern Med148198815261528
37. Verresen D, De Backer W, Vermeire PPulmonary hypertension and sickle hemoglobinopathy. Chest9819901042
38. Norris SL, Johnson C, Haywood LJLeft ventricular filling pressure in sickle cell anemia. J Assoc Acad Minor Phys319922023
39. Van Enk A, Visschers G, Jansen W, Statius van Eps LWMaternal death due to sickle cell chronic lung disease. Br J Obstet Gynaecol991992162163
40. Sutton LL, Castro O, Cross DJ, Spencer JE, Lewis JFPulmonary hypertension in sickle cell disease. Am J Cardiol741994626628
41. Castro OSystemic fat embolism and pulmonary hypertension in sickle cell disease. Hematol Oncol Clin North Am10199612891303
42. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 52-1983. Pulmonary hypertension associated with abnormal hemoglobin. N Engl J Med 1983;309:1627–1636.
43. Kaur K, Brown B, Lombardo FProstacyclin for secondary pulmonary hypertension (letter; comment). Ann Intern Med1322000165
44. Aboubakr SE, Girgis R, Swerdlow P. Pulmonary hypertension in sickle cell disease. Am J Respir Crit Care Med 1999;160:A144 (abstract).
45. Oppenheimer EH, Esterly JRPulmonary changes in sickle cell disease. Am Rev Respir Dis1031971858859
46. Haupt HM, Moore GW, Bauer TW, Hutchins GMThe lung in sickle cell disease. Chest811982332337
47. Grisaru D, Rachmilewitz EA, Mosseri M, Gotsman M, Lafair JS, Okon E, Goldfarb A, Hasin YCardiopulmonary assessment in beta-thalassemia major. Chest98199011381142
48. Du ZD, Roguin N, Milgram E, Saab K, Koren A. Pulmonary hypertension in patients with thalassemia major. Am Heart J 1997;134:532–537.
49. Finazzo M, Midiri M, D'Angelo P, Gallo C, Sparacia GV, Carcione A, Gattuso A, Lagalla R[The heart of the patient with beta thalassemia major. Study with magnetic resonance]. Radiol Med (Torino)961998462465
50. Aessopos A, Stamatelos G, Skoumas V, Vassilopoulos G, Mantzourani M, Loukopoulos DPulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. Chest10719955053
51. Aessopos A, Farmakis D, Karagiorga M, Voskaridou E, Loutradi A, Hatziliami A, Joussef J, Rombos J, Loukopoulos DCardiac involvement in thalassemia intermedia: a multicenter study. Blood97200134113416
52. Repka T, Hebbel RPHydroxyl radical formation by sickle erythrocyte membranes: role of pathologic iron deposits and cytoplasmic reducing agents. Blood78199127532758
53. Kuross SA, Hebbel RPNonheme iron in sickle erythrocyte membranes: association with phospholipids and potential role in lipid peroxidation. Blood72198812781285
54. Hebbel RP, Morgan WT, Eaton JW, Hedlund BEAccelerated autoxidation and heme loss due to instability of sickle hemoglobin. Proc Natl Acad Sci U S A851988237241
55. Hebbel RP, Eaton JW, Balasingam M, Steinberg MHSpontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest70198212531259
56. Rostagno C, Prisco D, Abbate R, Poggesi LPulmonary hypertension associated with long-standing thrombocytosis. Chest99199113031305
57. Bunn HFPathogenesis and treatment of sickle cell disease. N Engl J Med3371997762769
58. Platt OSSickle cell anemia as an inflammatory disease. J Clin Invest1062000337338
59. Platt OSThe acute chest syndrome of sickle cell disease. N Engl J Med342200019041907
60. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DREffect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia (see comments). N Engl J Med332199513171322
61. Charache SMechanism of action of hydroxyurea in the management of sickle cell anemia in adults. Semin Hematol3419971521
62. Atweh GF, Schechter ANPharmacologic induction of fetal hemoglobin: raising the therapeutic bar in sickle cell disease. Curr Opin Hematol82001123130
Correspondence and requests for reprints should be addressed to Mark T. Gladwin, M.D., Warren G. Magnuson Clinical Center, Critical Care Medicine Department, Building 10, Room 7D43, 10 Center Drive, MSC 1662, Bethesda, MD 20892-1662. E-mail:

Related

No related items
American Journal of Respiratory and Critical Care Medicine
164
11

Click to see any corrections or updates and to confirm this is the authentic version of record